Compare ANIK & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANIK | PLX |
|---|---|---|
| Founded | 1983 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.6M | 174.0M |
| IPO Year | 1996 | 1996 |
| Metric | ANIK | PLX |
|---|---|---|
| Price | $14.97 | $1.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $17.00 | $12.00 |
| AVG Volume (30 Days) | 115.6K | ★ 543.9K |
| Earning Date | 04-29-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.16 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $112,819,000.00 | $52,744,000.00 |
| Revenue This Year | $5.98 | $36.81 |
| Revenue Next Year | $7.42 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.90 | $1.34 |
| 52 Week High | $16.24 | $3.19 |
| Indicator | ANIK | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 52.03 | 31.07 |
| Support Level | $13.81 | $1.43 |
| Resistance Level | $15.74 | $2.14 |
| Average True Range (ATR) | 0.93 | 0.07 |
| MACD | -0.16 | -0.01 |
| Stochastic Oscillator | 69.44 | 3.77 |
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.